Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast Cancer

NCT04083963 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT04083963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04083963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast Cancer
Lead sponsor
University of Illinois at Chicago
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 9, 2019
Completion date
September 27, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer